Pane wikiwiki
Learn how to overcome on-resin peptide aggregation, hoʻololi paʻakikī, prep-HPLC purification, and endotoxin bottlenecks in biopharma peptide scale-up.
ʻO ka Mechanics Chemical o ka Hoʻohui ʻana i ka Resin ma nā ʻano Peptide Paʻakikī
ʻO ka peptide synthesis paʻa (SPSS) hilinaʻi i ka pehu mau a me ka hoʻonā ʻana o ka ulu ʻana o ka peptidyl-resin matrix. Eia naʻe, e like me ka lōʻihi o ke kaulahao peptide—e hoʻomaka ana ma waena o nā koena 5 a me 15—hiki i ka hoʻopaʻa ʻana o ka hydrogen intramolecular a me ka intermolecular hydrogen ke hoʻomaka i ka hoʻololi ʻana mai ka hoʻohālikelike ʻana i ka coil random i ka paʻa., kauoha i ka β-pepa lua.

Hoʻolaha ʻia ʻo Inter-Chain β-Sheet & Hoʻohāʻule ʻana
Ke ulu nei nā kaulahao peptide e hōʻuluʻulu i ke kākoʻo paʻa, hāʻule ka matrix resin a nalowale ka hiki ke pehu. Ke kanu kino nei kēia hiʻohiʻona i ka amine N-terminal, ka hana ʻana i nā pale steric e keʻakeʻa loa i ka laha ʻana o ka reagent. No laila, ʻO ka hoʻopau ʻana i ka Fmoc maʻamau a me ka ʻakika amino hoʻopili ʻana i nā hopena, e alakaʻi ana i nā kaʻina oki, holoi i nā mea haumia (des-amino acid byproducts), a me nā pane piha ʻole ʻaʻole hiki ke hoʻokuʻu ʻia i ka hoʻopau ʻana me nā manawa hoʻopili lōʻihi a i ʻole nā kiʻekiʻe reagent kiʻekiʻe..
ʻO nā kaʻina hydrophobic i loaʻa nā ʻakika amino a i ʻole nā lālā β-branched (e.g., ʻO Val, Me, Leu, Ua haʻi aku ʻo Phe, ʻO Tyr) pili loa i ka houluulu. ʻO nā haʻawina mechanistic hou e pili ana i ka hoʻohui peptide pili i ke kaʻina i paʻi ʻia ma Nature Chemistry (2026) hōʻike i ka hiki ke hoʻohaʻahaʻa i ka hoʻololi ʻana o ka hoʻololi ʻana i hoʻokahi ʻanuʻu i hui pū ʻia me ka hui inter-chain. >99% iho i lalo 70%. Ma luna o kahi 30-mer synthesis, he hāʻule ma ka awelika ʻanuʻu hua mai 99% i 90% e hoemi ana i ka hua mai 74% i lalo 4%.

ʻO ke ʻano hāʻule ʻole o ke kaʻina hana SPPS:
Solvated Chain (Random Coil) → Inter-Chain H-Bonding → β-Sheet Secondary Structure → Resin Shrinkage & Amine Burial(Pehu kiʻekiʻe, Ka hoohuli ana >99%) ——————————————————> (Nā ʻokiʻoki & Holoi >30%)
ʻO ka hoʻohaʻahaʻa haʻahaʻa: Pseudoproline Dipeptides, Hoʻomalu iwi kuamoʻo, a me na kokua haahaa
E hoʻopau i ka nucleation β-sheet i ka wā e hui ai, hoʻohana ka poʻe kemika kaʻina hana i nā hana i hoʻopaʻa ʻia:
-
Pseudoproline Dipeptides (Oxazolidines): Hoʻokomo ʻia ʻo Fmoc-X-Ser(bipi)-OH, Fmoc-X-Thr(bipi)-OH, a i ʻole Fmoc-X-Cys(bipi)-Hoʻokomo ʻo OH dipeptides i kahi apo oxazolidine reversible e hana nei ma ke ʻano he "kink" (cis-proline mimic) i ka iwi kuamoʻo peptide. Hoʻopau kēia i nā pūnaewele hoʻopaʻa hydrogen intermolecular a hoʻihoʻi i ka hoʻonā resin. Ma hope o ka ʻoki ʻana me ka waikawa trifluoroacetic maʻamau (TFA) cocktails, wehe nui ke apo oxazolidine e hoʻola hou iā Ser, ʻO Thr, a i ʻole Cys koena.
-
Nā Pūʻulu Hoʻomalu Iwikuā: Hiki ke hoʻololi i ka N-alkylation me ka hoʻohana ʻana i nā hui pale manawaleʻa e like me Hmb (2-hydroxy-4-methoxybenzyl) a i ʻole Dmb (2,4-dimethoxybenzyl) pale i ka hoʻopaʻa hydrogen iwi kuamoʻo amide. Waiho ʻia kēlā me kēia 5 i 6 koena, Mālama kēia mau pūʻulu i ka maʻi kaulahao i ka wā synthesis.
-
Hoʻohuihui Peptide ʻO ka hoʻouka ʻana i ka Resin: ʻO nā resins hoʻouka kiʻekiʻe (0.6–1.0 mmol/g) e hoʻonui i ka pilina ma waena o ke kaulahao ma ke kau ʻana i nā kaulahao ulu ma kahi kokoke. Ke hoʻohana nei i nā resins haʻahaʻa haʻahaʻa (0.15–0.25 mmol/g) ma ka polyethylene glycol (PEG)-grafted polystyrene a i ʻole nā matrices PEG maʻemaʻe (e like me ChemMatrix) hoʻonui i ka mamao ma waena o nā kaulahao, hoʻomaikaʻi nui i ka solvation no ka paʻakikī, nā pahu hopu hoʻohuihui.
-
Māmā & ʻO ka wikiwiki o ka microwave: Manao wela i hoomaluia (50°C–80°C) i ka wā o ka hui ʻana a me ka hoʻopau ʻana i nā ʻanuʻu e hoʻopau i nā ʻupena hoʻohui ʻole covalent nāwaliwali, ka wikiwiki ʻana i nā kinetics pane ʻole me ka hoʻolaha ʻana i ka racemization ke hoʻopili ʻia me nā reagents hoʻohui haʻahaʻa e like me DIC/Oxyma Pure.
Nā Hoʻololi Paʻakikī & Nā Paʻa Kūleʻa i nā Peptides Nui
ʻO nā lāʻau lapaʻau peptide hou e hoʻonui i ka laina laina, nā kaʻina i hoʻololi ʻole ʻia. Ke koi nei nā pipelines Biopharma i nā framework multi-cyclic, ʻO ka lipid kikoʻī pūnaewele a i ʻole ka conjugation PEG, a me nā lepili hana kūikawā no ka hoʻopaʻa ʻana i nā profile pharmacokinetic a me ka pilina paʻa ʻana.
Ke hoʻokele nei i ka pani pani ʻana i ke apo Multi-Disulfide & Regioselective Oxidation
ʻO nā peptide i loaʻa nā mea paʻa disulfide he nui (e like me linaclotide analogues, ziconotide, a i ʻole nā peptides bicyclic i kāohi ʻia) koi i ka mana koʻikoʻi ma luna o nā ala peʻe e pale aku i ka scrambled, nā isomers disulfide maoli. ʻO ka hoʻoheheʻe ʻia ʻana o ka ea o nā kaʻina poly-cysteine e hāʻawi pinepine i nā hui thermodynamic paʻakikī i paʻakikī loa e hoʻomaʻemaʻe ma o prep-HPLC..
No ka hoʻokō maʻemaʻe, hoʻokumu ʻana i ka disulfide regioselective, Hoʻohana ʻia nā hoʻolālā hui pale cysteine orthogonal:
-
Paa 1 (Ua haʻi ʻo Trt): Hoʻokaʻawale ʻia i ka wā o ka wehe ʻana i ka resin TFA maʻamau; oxidized mua ma ka liʻiliʻi aqueous buffer a i ʻole DMSO / hui wai.
-
Paa 2 (Acm / Mmt): Paʻa a maʻalahi ka ʻāpana TFA; koho ʻia ma ka resini a i ʻole i ka hopena me ka hoʻohana ʻana i ka iodine (I₂) a i ʻole thallium(III) trifluoroacetate.
-
Paa 3 (StBu / Pyth): Wehe ʻia me ka dithiothreitol (DTT) a i ʻole trialkylphosphines ma mua o ka cyclization kuhikuhi hope.
Hoʻokō i kuhikuhi ʻia, ʻO ka oxidation step-wise e hōʻoia i ka pilina maoli, ke koi ʻana i ka maʻemaʻe regioselective ma luna 90% ma mua o ka hoʻopololei prep-HPLC hope loa.
ʻO ka hoʻolālā ʻokiʻoki ʻana Tri-Disulfide Orthogonal:
-
ʻanuʻu 1 (Hoʻohu ʻia e ka ea):
Linear Sequence[Cys1/4(Ua haʻi ʻo Trt), Cys2/5(Acm), Cys3/6(Mob)] → TFA Cleavage & ʻOke ea maʻalahi →1-Disulfide Intermediate[Hoʻokumu ʻia ʻo Cys1-Cys4] -
ʻanuʻu 2 (Iodine Oxidation):
1-Disulfide Intermediate→ Iodine (I₂) Lapaʻau →2-Disulfide Intermediate[Kiki1-Kiki4 & Hoʻokumu ʻia ʻo Cys2-Cys5] -
ʻanuʻu 3 (Thallium/TFA Oxidation):
2-Disulfide Intermediate→ Ua hoike mai o Tl(CF₃COO)₃/TFA lapaʻau →Fully Folded Monomer[ʻŌiwi Cys1-Cys4, Kiekie2-Kiekie5, Cys3-Cys6 Hoʻohui]
Lipidation, PEGylation, a me ka Isotope/Fluorescent Tagging ma ka Scale
Hoʻohui i nā kaulahao momona momona (e.g., ʻakika palmitic, ʻakika myristic, nā spacers diacid no ka hoʻopaʻa albumin) a i ʻole nā kaulahao PEG monodisperse e hoʻonui i ka hapalua o ke ola o ka peptide (t 1/2) ola. Eia naʻe, Hoʻololi nui nā kaulahao acyl momona hydrophobic i ka solubility i ka wā hana SPPS.
Ke hana nei i nā hoʻololi kikoʻī pūnaewele, ka hoʻohana ʻana i nā hui pale Lys orthogonal—e like me Lys(ʻO Dde) aiʻole Lys(ivDde)—ʻae i ka wehe ʻana i ka hydrazine-mediated deprotection me ka hoʻopilikia ʻole i ka iwi kuamoʻo Fmoc/tBu pūʻulu pale.. Hoʻohana kūikawā paʻakikī ʻO nā Peptides Synthetic nā hoʻololi peptide a me ka hana ma waena 300+ Hiki i nā koho pūʻulu hana ke hoʻohui ʻia i nā huaʻōlelo fluorescent (FITC, Cy5), nā isotopes paʻa (^{13}C, ^{15}N), a i ʻole nā mea hoʻohui pili ʻelua me ka kikoʻī pūnaewele paʻa.
Hoomaemae i lalo & Kūʻē Kūʻē: Hoʻoholo i ka Prep-HPLC Bottleneck
Hoʻoponopono pololei ka hoʻonui ʻana i ka synthesis i ka ʻoihana hoʻomaʻemaʻe iho. I ka hana peptide nui, ʻO ka hoʻomaʻemaʻe prep-HPLC e hōʻike ana i ka 60% o ka huina o na koina hana ma muli o ke kiʻekiʻe o ka mobile-phase solvent hoʻohana, ʻaʻahu kūmau, a me ka haʻahaʻa haʻahaʻa haʻahaʻa i ka wā e hoʻoholo kokoke ana i ka holoi ʻana i nā haumia holoi.
Chromatographic Resolution of Deletion Sequences and Diastereomers
ʻO ke koʻikoʻi i ka hoʻonā prep-HPLC maikaʻi ke koho kemika kolamu a me ka ʻenekini gradient. ʻOiai ʻo ka C18 maʻamau ka hoʻopaʻa paʻa ʻana no nā peptides linear hydrophobic, Loaʻa pinepine nā kaʻina hana paʻakikī a i ʻole amphipathic mai ke koho ʻana i ka pae paʻa:
-
Nā Māhele C8 a me C4: E hōʻemi i ka hoʻopaʻa ʻana a me ka huelo kiʻekiʻe no nā peptides hydrophobic a i ʻole lipidated.
-
Phenyl-Hexyl & PFP (Pentafluorophenyl) Māhele: Hāʻawi i nā pilina pi-pi i hoʻonui ʻia no ka hoʻonā ʻana i nā diastereomers ʻala a me nā koena racemized (e.g., ʻO nā ʻano like ʻole D-His a i ʻole D-Trp).
-
Mahana & Hoʻololi pH: Ke holo nei i nā kolamu hoʻomākaukau i nā wela kiʻekiʻe (40°C–60°C) a i ʻole ka hoʻoponopono ʻana i ka pH mobile-phase (me ka hoʻohana ʻana i ka triethylammonium phosphate a i ʻole ammonium acetate buffers) hoʻololi i ka hoʻohālikelike ʻana o ka ʻōnaehana lua i ka hoʻonā, ka hoʻokaʻawale ʻana i nā kaʻina holoi holoi (n-1 ʻano) mai ka API lōʻihi piha.
No ke kōkua: Hoʻonui i ka hoʻouka ʻana
Ka hoʻoheheʻe ʻana i ka peptide crude i loko o nā solubilizer organik ikaika e like me ka dimethyl sulfoxide (DMSO) a i ʻole hexafluoroisopropanol (HFIP) ma mua o ka hoʻouka ʻana i ke kolamu prep-HPLC e pale i ka ua ma ke kolamu. Ka hoʻoheheʻe ʻana i ka plug i hoʻokomo ʻia i loko o ka laina me ka pae paʻa wai (hoʻokuʻi ʻia) hoʻokala i ke ʻano kiʻekiʻe a hoʻopālua i ka hiki ke hoʻouka hoʻomākaukau i kēlā me kēia holo.
Ka ʻike hihia: Nuance Hoʻololi Kūʻē ʻOihana
I nā hoʻolaha hoʻonui i ʻoi aku ka nui 100 kalaima, Hiki ke alakaʻi i ka hoʻololi ʻana o ka pH kūloko a me ka hōʻuluʻulu hoʻololi. Ke hoʻokō ʻana i kahi loop gradient recirculation me ke anuanu 0.1 M ammonium acetate (4°C) pale i ka nalo o ka solubility i ka loa'a 'ana o ka ho'ololi kū'ē kū'ē me <0.5 wt% koena TFA.
Kūʻai Kūʻē: Ke hoʻololi ʻana mai ka TFA i ka Acetate a me nā paʻakai Chloride
Hoʻohana ka hoʻomaʻemaʻe RP-HPLC maʻamau i ka waikawa trifluoroacetic (TFA) ma ke ʻano he reagent hoʻohui ion e hoʻokala i nā piko chromatographic a hoʻopau i nā kaulahao ʻaoʻao amino acid. (ʻO Arg, Lys, ʻO kāna). No laila, Hoʻokaʻawale ʻia nā peptides nui i hoʻomaʻemaʻe ʻia e like me nā paʻakai TFA i loaʻa a hiki i ka 10%-15% mau mea hoʻopaʻa trifluoroacetate counterions.
No ka preclinical in vitro assays, haʻawina holoholona, a me na hoao kanaka, ʻO ke koena o ka TFA he mau mea ʻawaʻawa nui, ke keʻakeʻa nei i ka hoʻonui ʻana o ka cell a me ka huikau ʻana i nā hopena immunological. Pono ka hoʻololi ʻana i nā paʻakai TFA i nā counterions-grade pharmaceutical:
-
Hoʻololi Acetate: Hoʻouka ʻia ka hopena peptide i hoʻomaʻemaʻe ʻia ma ke kolamu RP-HPLC lua, holoi me 0.1 M ammonium acetate a i ʻole ka sodium acetate buffer, a hoʻoheheʻe ʻia me ka acetonitrile wai.
-
Hoʻololi Kloride: No nā peptides pahuhopu e koi ana i ka solubility kiʻekiʻe a me ke kūpaʻa, holoi i ke kolamu me ka waika hydrochloric dilute (0.01 M HCl) hoohuli i na paakai chloride.
-
Hōʻoia Analytical: Kromatography kinoea poʻo (GC) a i ʻole chromatography ion (IC) hōʻoia i ke koena TFA maʻiʻo ua hoemi i lalo 1.0 wt%, e pili ana i nā kūlana biopharma honua.
Papa 100 Nā Mana Hoʻomaʻemaʻe Ultra-Sterile & Nā Palekana Endotoxin
Ma ka noiʻi preclinical a me ka hoʻomohala lāʻau, ʻOi aku ka maikaʻi o ka peptide ma mua o ka hoʻomaʻemaʻe kemika HPLC. ʻO ka hoʻohaumia microbial, nā mea lele ea, a me nā endotoxins bacteria (lipopolysaccharides, LPS) hōʻike i nā pilikia koʻikoʻi koʻikoʻi. Hiki ke ho'āla i nā pae endotoxin i nā pūʻulu peptide maʻamau 4 (TLR4), ka hoʻoulu ʻana i nā pane ʻino maikaʻi maikaʻi ʻole i ka hoʻāʻo ʻana ma ke kelepona a i ʻole ke kuni a me ka anaphylaxis i nā ʻano holoholona.
Kūleʻa Kūleʻa Kūleʻa Kūleʻa:
Synthesis & Cleavage → Prep-HPLC & Counterion Exchange → Class 100 Isolation → Final Freeze-Drying(Kaiapuni SPPS maʻamau) → (TFA i ka Acetate hoʻololi) → (ISO 5 HEPA Kanana Pua) → (LAL Endotoxin <0.01 EU/mg)
Microbial & ʻO ka hoʻopaʻa ʻana i nā ʻāpana ma hope o ka hoʻomaʻamaʻa ʻana
E hōʻoia i ka palekana olaola, hana ma hope o ka ʻoki ʻana, hoʻololi kūʻē, lyophilization, a ʻo ka hoʻopiha piha ʻana i ka vial hope pono e kū i loko o nā kūlana kaiapuni i hoʻopaʻa ʻia.
ʻO ka Nā alakaʻi alakaʻi o ka American Peptide Society no ka hoʻēmi ʻana i ka hōʻuluʻulu SPPS a me ka lawelawe ʻana o ka lumi maʻemaʻe e hōʻike ana i ka mālama ʻana i ka papa haʻahaʻa i ka wā o ka hoʻoheheʻe ʻana a i ʻole ka maloʻo maloʻo e hoʻolauna i ka bioburden ambient. Ka hoʻohana ʻana i hoʻohui ʻia Papa 100 sterility lumi maʻemaʻe a me QC analytical ʻoihana—e hana ana ma lalo o ISO 5 ʻO nā puʻupuʻu kahe ea laminar me ka kānana HEPA - pale i ka komo ʻana o nā ʻāpana a me ka microbial colonization i ka wā kaʻawale huahana hope loa..
ʻO ka hoʻāʻo ʻana o LAL Endotoxin nui no In Vitro a me In Vivo Safety
Pono kēlā me kēia pūʻulu peptide maʻamau i koho ʻia no ka loiloi olaola e hoʻāʻo ʻia:
-
Hōʻike LAL Chromogenic: ʻO Limulus Amebocyte Lysate nui (LAL) ka ho'āʻo a i ʻole ka hui hou ʻana o Factor C (rFC) ʻO nā hōʻike fluorometric e hoʻohālikelike i nā pae endotoxin.
-
Nā paepae ʻae ʻia ʻo Biopharma: Loaʻa pinepine nā peptides noiʻi maʻamau i nā pae endotoxin >10 EU/mg. No ka moʻomeheu kelepona mua koʻikoʻi, nā hoʻokolohua organoid, a in vivo hooponopono makua, Pono e mālama ʻia nā pae endotoxin <0.01 i 0.1 EU/mg.
-
Wai Maʻemaʻe Ultra & Mea aniani Depyrogenated: Ka hana ʻana i nā ʻanuʻu a pau ma hope o ka hoʻomaʻemaʻe ʻana me ka wai ʻole pyrogen-free no ka Injection (WFI) a me nā ipu aniani i hoʻopau ʻia i ka wela (250°C no 30 minuke) hoʻopau i ka ʻino endotoxin ma ke kumu.
Matrix Hoʻoholo: Ke koho ʻana i ka Peptide CDMO/CRO Hoa
Pono ke koho ʻana i kahi mea kūʻai synthesis maʻamau e loiloi i nā hiki ʻenehana ma waena o ka paʻakikī kemika, ʻoʻoleʻa kālailai, a me nā ʻōnaehana hoʻokele maikaʻi. Hōʻike ka matrix ma lalo nei i nā koina loiloi koʻikoʻi i ke koho ʻana i hoa no ka peptide synthesis scale-up:
|
Nā Koina Loiloi |
Mea hoʻolako helu maʻamau |
ʻO R&D Hoa Hoʻohui |
Hoʻohui ʻia ʻo Ultra-Sterile Platform (MOL Changes) |
|---|---|---|---|
|
ʻenehana Synthesis |
SPPS maʻamau |
ʻO ka Microwave SPPS |
SPPS huila, LPPS & ʻO ka hoʻoheheʻe microbial |
|
Ka lōʻihi o ke kaʻina hana |
30– 40 mau ʻakika amino |
50-70 mau ʻakika amino |
A hiki i 100+ nā ʻakika amino |
|
Hiki ke hoʻololi |
Nā hōʻailona kumu N-terminal/C-terminal |
Kaʻapuni maʻamau & peptides phosphorylated |
300+ hui hana, lipid/PEG, multi-disulfide |
|
Hoʻoponopono lumi hoʻomaʻemaʻe |
Paena lab maʻamau |
Papa 10,000 (ISO 7) |
Papa 100 (ISO 5) ʻO ka lumi hoʻomaʻemaʻe Ultra-Sterile |
|
Hoʻomalu Endotoxin Hana ʻia ʻo Peptide |
ʻAʻole i hoʻāʻo ʻia / >10 EU/mg |
Koho (<1.0 EU/mg) |
Kūlana (<0.01 i 0.1 EU/mg, Ua hoʻāʻo ʻia ʻo LAL) |
|
ʻAha Pūʻulu |
ʻO ka nānā ʻana i ka milligram |
Nā pūʻulu pālākiō gram |
Milligrams i Multi-Kilogram IND/Kalepa |
|
Palapala Pono |
MS kumu & HPLC |
CoA maʻamau |
Hoʻopiha HRMS, RP-HPLC chromatograms, COA |
Ke loiloi i nā hoa no ke kākoʻo papahana lōʻihi, Loaʻa nā mea hoʻomohala biopharma i ka leveraging nā lawelawe hana peptide synthesis maʻamau e hāʻawi i ka hoʻololi ʻenehana maʻemaʻe mai ka milligram exploratory screening a hiki i ka kilo IND-hiki i ka hana.
Nīnau pinepine (FAQ)
He aha ke kumu e hāʻule ai ka hua i ka wā o ka peptide synthesis scale-up?
ʻO ka hāʻule nui ʻana o ka hua i ka wā o ka hoʻonui ʻia ʻana ma muli o ka hui ʻana o ka β-sheet on-resin o nā kaʻina waikawa amino hydrophobic.. Ke piʻi nei ka lōʻihi o ke kaulahao, ʻO ka hāʻule ʻana o ka hoʻopaʻa ʻana i ke kaulahao hydrogen e hōʻemi i ka pehu ʻana o ka resin a kanu i nā amine N-terminal, e alakaʻi ana i ka hoʻopili piha ʻole ʻana a me ka ʻoki ʻana i nā kaʻina holoi.
Pehea e pale ʻia ai ka hui ʻana o ka peptide on-resin i ka wā synthesis?
Kāohi ʻia ka hoʻohui ʻana ma ka resin ma ka hoʻokomo ʻana i nā dipeptides pseudoproline (ma nā kūlana Ser/Thr/Cys), me ka hoʻohana ʻana i nā pūʻulu pale N-kuʻe no ka manawa pōkole (Hmb/Dmb), hōʻemi i ka hiki ke hoʻouka resin i 0.15-0.25 mmol/g, a me ka hoʻohana ʻana i ka wela wela o ka microwave (50°C–80°C) i ka wā e hoʻohui ai.
No ke aha e pono ai ka hoʻololi counterion TFA no nā peptides therapeutic?
Hoʻohana ka hoʻomaʻemaʻe prep-HPLC maʻamau i ka waikawa trifluoroacetic (TFA), waiho 10-15 wt% koena TFA i loko o ka peptide huahana. Hōʻike ʻo TFA i ka ʻawaʻawa kelepona a keʻakeʻa i nā hoʻokolohua biological hana. ʻO ka hoʻololi ʻana i nā paʻakai TFA i ka acetate a i ʻole nā paʻakai chloride e hoʻemi i ke koena TFA i <1.0 wt%, e hōʻoia ana i ka hoʻohālikelike ʻana me nā haʻawina in vitro a me in vivo.
He aha ka pae endotoxin e ʻae ʻia no ka hoʻāʻo ʻana i nā cell a me nā haʻawina vivo?
No nā hoʻokolohua biochemical maʻamau, nā pae endotoxin ma lalo 1.0 Hiki ke ʻae ʻia ka EU/mg. Eia naʻe, no nā moʻomeheu kelepona mua koʻikoʻi, organoids, a me nā hiʻohiʻona holoholona, Pono e hoʻomalu pono ʻia nā pae endotoxin <0.01 i 0.1 EU/mg no ka pale ʻana i ka hoʻoulu ʻana o TLR4 a me nā mea kikoʻī kelepona ʻole.
Nā ʻanuʻu hou aʻe no Biopharma R&D Nā papahana
ʻO ka holomua ʻana i kahi kaʻina peptide paʻakikī mai ka hoʻolālā molekala a hiki i ka reproducible physical batch material pono e hoʻolikelike i ka loea synthesis chemical me nā mana kaiapuni.. ʻO ka pale ʻana i nā bottlenecks aggregation i ka hoʻomaka ʻana o ka hoʻomohala ʻana e pale i nā manawa o ka papahana a hōʻoia i ka hana olaola pono.
Inā hoʻokele kāu hui i ka hōʻuluʻulu ʻano paʻakikī, pani apo-disulfide apo, a i ʻole nā palena endotoxin koʻikoʻi no nā haʻawina preclinical e hiki mai ana:
-
Kūkākūkā ʻenehana: E nānā i kāu hoʻolālā kaʻina, hydrophobic profile, a me nā koi hoʻololi me ka ʻike peptide chemists ma ka Hoʻololi ʻo MOL i ka paepae peptide maʻamau.
-
Ka Loiloi Pono: E noi i ka hiki mua a me ka hoʻonui ʻana i ka loiloi no nā pahuhopu kaʻina paʻakikī ma o nā lawelawe hana peptide synthesis maʻamau.
-
ʻO ka maʻemaʻe & QC hōʻoia: E nānā i nā pūʻolo ʻikepili analytical, me ke kiko kikoʻī HRMS, RP-HPLC chromatograms, a me nā palapala hōʻoia hoʻāʻo endotoxin LAL i kūpono i kāu mau kūlana noiʻi lapaʻau.
